News Image

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Provided By GlobeNewswire

Last update: Nov 15, 2024

50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial

Overall, in Cohort A1, 25% of patients achieved functional cure

Read more at globenewswire.com

ARBUTUS BIOPHARMA CORP

NASDAQ:ABUS (7/25/2025, 8:00:00 PM)

After market: 3.22 0 (0%)

3.22

-0.02 (-0.62%)



Find more stocks in the Stock Screener

Follow ChartMill for more